Company intelligence / Profile preview

Caribou Office

Berkeley, California, United Statescaribouoffice.com ↗

Ownership: Private
Employees: ~108
Development stage: Commercial

Overview

Caribou Biosciences is a clinical-stage biotech company pioneering next-generation CRISPR genome editing to develop allogeneic, off-the-shelf CAR-T and CAR-NK therapies. Its lead asset, CB‑010, has shown durable responses in Phase 1 for large B-cell lymphoma. As of April 2025, the company has narrowed its focus to two oncology assets after discontinuing autoimmune and AML programs due to strategic reprioritization and workforce reduction.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapyCRISPR-based therapyAllogeneic cell therapyCAR-NK cell therapy (preclinical)
Industry: Biotech

Partnerships

AbbVieThe Leukemia & Lymphoma Society

Beyond the preview

Go deeper on Caribou Office.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caribou Office.

Explore the full profile